• Nile Red in Laryngeal Cancer Research: Evidence Boundaries

  2026-10-13

  A source-grounded overview of what a 2025 laryngeal cancer biomarker study reported, what Nile Red can conceptually contribute to lipid-focused research, and why the two bodies of evidence should not be treated as directly connected.

• SMPD4, Ceramide and Primary Cilia Development

  2026-10-13

  A 2024 Development study uses mouse and human iPSC models to examine how SMPD4-associated sphingolipid dysfunction may cause microcephaly and cerebellar hypoplasia. Its findings support a role for SMPD4-dependent ceramide production in primary-cilium integrity, neural progenitor survival and cerebellar development, while remaining limited by model-system and mechanistic boundaries.

• GSK343 and the Limits of EZH2 Evidence

  2026-10-12

  GSK343 is a reported EZH2 inhibitor used as an in vitro epigenetic research tool. Its biochemical and cell-line activity should not be conflated with evidence that EZH2 inhibition reproduces CBX2-dependent immune effects or improves cancer immunotherapy.

• Wnt Metabolism, Osteogenesis, and IWP-L6

  2026-10-12

  The cited study links Wnt3a-driven osteogenesis to O-GlcNAcylation, PDK1 stabilization, and aerobic glycolysis. IWP-L6 addresses a different level of Wnt biology as a supplier-described Porcupine inhibitor, and the available evidence does not show that it was used in the bone study or that its reported developmental effects translate to bone anabolism.

• BRD4770 and the BRD4–RAC1 Breast Cancer Study

  2026-10-11

  A source-grounded overview of the study’s research question, conceptual design, reported findings, evidence strength, and limitations, with a clear distinction between BRD4770 and the compounds actually evaluated.

• RB1 Loss and the Earliest Cell of Retinoblastoma

  2026-10-10

  A 2026 Cell Death & Disease study uses RB1-deficient human retinal organoids and longitudinal single-cell analysis to distinguish the retinal cells most sensitive to RB1 loss from the earliest cellular origin of retinoblastoma. The work identifies ATOH7+/RXRγ+ nascent cone precursors as the population that ultimately drives tumorigenesis, while defining a retinocytoma-like intermediate after monoallelic RB1 loss.

• Ran Lactylation Links Lactate to Astrocyte Polarization

  2026-10-09

  A 2026 study identifies Ran lactylation at lysine 123 as a non-histone mechanism linking lactate accumulation to STAT3 nuclear transport and A2-like astrocyte polarization after oxygen-glucose deprivation/reoxygenation. Its evidence supports a SIRT1-regulated lactate–Ran–STAT3 axis, while remaining limited by model specificity and the need for further validation of the underlying enzymatic relationship.

• 40-Hz Flicker and Retinal Amyloid Clearance

  2026-10-09

  A 2026 mouse study reports that 40-Hz light flicker increases retinal MHC-II expression, activates MHC-II-positive microglia, and improves clearance of amyloid-β oligomers. Pharmacological suppression of microglial activity eliminated these effects, supporting a microglia-dependent mechanism while leaving the direct role of MHC-II unresolved.

• Transcription Termination Protects DNA After WEE1 Inhibition

  2026-10-08

  Landsverk et al. show that transcription termination limits DNA damage and cell death after WEE1 inhibition by helping prevent transcription–replication conflicts. Their findings identify termination machinery as a mechanistic determinant of replication stress and support further study of combination strategies involving WEE1 and transcriptional regulation.

• Transcription Termination After WEE1 Inhibition

  2026-10-08

  A 2026 Nucleic Acids Research study identifies transcription termination as an active genome-protection mechanism after WEE1 inhibition. Its findings connect read-through transcription with transcription–replication conflicts, S-phase DNA damage, and cancer-cell survival, while highlighting a possible rationale for combination treatment strategies.

• hCG, H3K27 Methylation, and CXCL10 in Decidua

  2026-10-07

  Silasi et al. report that human chorionic gonadotropin suppresses CXCL10 in decidual stromal cells by promoting EZH2-associated H3K27me3 at a defined CXCL10 promoter region. The study links a placental endocrine signal to chromatin regulation and reduced CD8-cell recruitment, while also defining important boundaries for interpreting the findings outside human decidual biology.

• GSK126 and EZH2: Research Context and Evidence

  2026-10-07

  GSK126 is a research tool for examining EZH2–PRC2 chromatin regulation. Evidence from astrocyte HIV-latency research supports a role for H3K27me3 in Tat-associated latency, while oncology applications remain broader supplier-described contexts requiring independent primary studies.

• GSK126 and EZH2: Evidence Across Cancer and Pain

  2026-10-06

  GSK126 is a research compound used to interrogate EZH2 and PRC2-dependent epigenetic regulation. This overview compares vendor-described oncology applications with peer-reviewed evidence linking EZH2 to microglial autophagy and neuropathic pain, while emphasizing provenance, translational limits, and the distinction between EZH2 biology and evidence specifically attributable to GSK126.

• Minocycline HCl in EV Research: An Evidence Map

  2026-10-06

  Minocycline HCl is examined here as a mechanistic comparator for scalable extracellular-vesicle research, not simply as an antibacterial or neuroprotective reagent. This evidence-focused analysis connects minocycline hydrochloride biology with the 2025 EPSC-derived MSC-EV platform while defining what the study does—and does not—demonstrate.

• RGFP966 and HO-1: Interpreting Enzyme Activity

  2026-10-05

  RGFP966 offers a pharmacological lens for examining HDAC3-linked regulation, while activity-based HO-1 imaging reveals why expression data alone can be misleading. This article connects those concepts without treating a mechanistic hypothesis as a reported result.

8739 records 4/583 page Previous Next 12345 下5页 Last page